Anti cancer quinolone.
Induces site-selective DNA damage by intercalating DNA and inhibiting topisomerase II, leading to apoptosis.
Combined with cytarabine in relapsed or refractory acute myelogenous leukemia median overall survival 7,1months, 29%complete remission rate, and median leukemia survival 14.4 months (Stuart RK).